Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma

BACKGROUND: Ficlatuzumab, a humanised hepatocyte growth factor (HGF) IgG1κ inhibitory monoclonal antibody, was evaluated for recommended phase II dose (RP2D), safety, pharmacokinetics (PKs), antidrug antibody (ADA), pharmacodynamics (PDs) and antitumour activity as monotherapy or combined with erlot...

Descripción completa

Detalles Bibliográficos
Autores principales: Patnaik, A, Weiss, G J, Papadopoulos, K P, Hofmeister, C C, Tibes, R, Tolcher, A, Isaacs, R, Jac, J, Han, M, Payumo, F C, Cotreau, M M, Ramanathan, R K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102944/
https://www.ncbi.nlm.nih.gov/pubmed/24901237
http://dx.doi.org/10.1038/bjc.2014.290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102944/
https://www.ncbi.nlm.nih.gov/pubmed/24901237
http://dx.doi.org/10.1038/bjc.2014.290

Ejemplares similares